High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion

Clinical Cancer Research

Volumn 5, Issue 6, 1999, Pages 1347-1352

  Takimoto, Chris H ^a,b   Yee, Lorrin K ^a,c   Venzon, David J ^a   Schuler, Barbara ^a   Grollman, Frank ^a   Chabuk, Chetin ^a   Hamilton, J Michael ^a   Chen, Alice P ^a   Allegra, Carmen J ^a   Grem, Jean L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINATE CALCIUM; SPARFOSIC ACID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHRONOTHERAPY; COLONIC NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECTAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TIME FACTORS;

EID: 0033045023     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Grem, J. L. 5-Fluoropyrimidines. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, Ed. 2, pp. 149-211. Philadelphia: Lippincott-Raven Publishers, 1996.
2. Seifert, P., Baker, L. H., Reed, M. L., and Vaitkevicius, V. K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer (Phila.), 36: 123-128, 1975.
3. Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., and Fryer, J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol., 7: 425-432, 1989.
4. Hansen, R. M., Ryan, L., Anderson, T., Krzywda, B., Quebbeman, E., Benson, A. R., Haller, D. G., and Tormey, D. C. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J. Natl. Cancer Inst., 88: 668-674, 1996.
5. Weinerman, B., Shah, A., Fields, A., Cripps, I. C., Wilson, K., McCormick, R., Temple, W., Maroun, J., Bogues, W., Pater, J., and Zee, B. Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am. J. Clin. Oncol., 15: 518-523, 1992.
6. Leichman, C. G., Fleming, T. R., Muggia, F. M., Tangen, C. M., Ardalan, B., Doroshow, J. H., Meyers, F. J., Holcombe, R. F., Weiss, G. R., Mangalik, A., and Macdonald, J. S. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J. Clin. Oncol., 13: 1303-1311, 1995.
7. Kish, J. A., Ensley, J. F., Jacobs, J., Weaver, A., Cummings, G., and Al-Sarraf, M. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer (Phila.), 56: 2740-2744, 1985.
8. von Roemeling, R., and Hrushesky, W. J. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J. Clin. Oncol., 7: 1710-1719, 1989.
9. Hrushesky, W. J., von Roemeling, R., Lanning, R. M., and Rabatin, J. T. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J. Clin. Oncol., 8: 1504-1513, 1990.
10. Levi, F., Soussan, A., Adam, R., Caussanel, J. P., Metzger, G., Jasmin, C., Bismuth, H., Smolensky, M., and Misset, J. L. A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. J. Infus. Chemother., 5: 153-158, 1995.
11. Bjarnason, G. A., Kerr, I. G., Doyle, N., Macdonald, M., and Sone, M. Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients. Cancer Chemother. Pharmacol., 33: 221-228, 1993.
12. Levi, F. A., Zidani, R., Vannetzel, J. M., Perpoint, B., Focan, C., Faggiuolo, R., Chollet, P., Garufi, C., Itzhaki, M., Dogliotti, L., Iacobelli, S., Adam, R., Kunstinger, F., Gastiaburu, J., Bismuth, H., Jasmin, C., and Misset, J. L. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl. Cancer Inst., 86: 1608-1617, 1994.
13. Smaaland, R., Laerum, O. D., Lote, K., Sletvold, O., Sothern, R. B., and Bjerknes, R. DNA synthesis in human bone marrow is circadian stage dependent. Blood, 77: 2603-2611, 1991.
14. Buchi, K. N., Moore, J. G., Hrushesky, W. J., Sothern, R. B., and Rubin, N. H. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology, 101: 410-415, 1991.
15. Harris, B. E., Song, R. L., He, Y. J., Soong, S. J., and Diasio, R. B. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochem. Pharmacol., 37: 4759-4762, 1988.
16. Harris, B. E., Song, R., Soong, S. J., and Diasio, R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50: 197-201, 1990.
17. Zhang, R., Lu, Z., Liu, T., Soong, S. J., and Diasio, R. B. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res., 53: 2816-2822, 1993.
18. Petit, E., Milano, G., Levi, F., Thyss, A., Bailleul, F., and Schneider, M. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res., 48: 1676-1679, 1988.
19. Grem, J. L., Yee, L. K., Venzon, D. J., Takimoto, C. H., and Allegra, C. J. Inter-and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother. Pharmacol., 40: 117-125, 1997.
20. Fleming, R. A., Milano, G., Thyss, A., Etienne, M. C., Renee, N., Schneider, M., and Demard, F. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res., 52: 2899-2902, 1992.
21. Lu, Z., Zhang, R., and Diasio, R. B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res., 53: 5433-5438, 1993.
22. Yee, L. K., Allegra, C. J., Steinberg, S. M., and Grem, J. L. Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon α-2a. J. Natl. Cancer Inst., 84: 1820-1825, 1992.
23. Grem, J. L., McAtee, N., Steinberg, S. M., Hamilton, J. M., Murphy, R. F., Drake, J., Chisena, T., Balis, F., Cysyk, R., Arbuck, S. G., Sorensen, J. M., Chen, A. P., Goldstein, L., Jordan, E., Setser, A., Goldspiel, B., DeCarvalho, M., and Allegra, C. J. A Phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma. Cancer Res., 53: 4828-4836, 1993.
24. Levi, F., Soussan, A., Adam, R., Caussanel, J. P., Metzger, G., Misset, J. L., Descorps-Decleres, Kustlinger, F., Lorphelin, D., Jasmin, C., Bismuth, H., Reinberg, A., and Mathe, G. Programmable-in-time pumps for chronotherapy of patients (PTS) with colorectal cancer with 5-day circadian-modulated venous infusion of 5-fluorouracil (CVI-SFUra). Proc. Am. Soc. Clin. Oncol., 8: 111, 1989.
25. Grem, J. L., McAtee, N., Murphy, R. F., Balis, F. M., Steinberg, S. M., Hamilton, J. M., Sorensen, J. M., Sartor, O., Kramer, B. S., Goldstein, L. J., Gay, L. M., Caubo, K. M., Goldspiel, B., and Allegra, C. J. A pilot study of interferon α-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J. Clin. Oncol., 9: 1811-1820, 1991.
26. Tong, Y. L. Parameter estimation in studying circadian rhythms. Biometrics, 32: 85-94, 1976.
27. Fleming, G. F., Schilsky, R. L., Mick, R., O'Brien, S. M., Vogelzang, N. J., and Ratain, M. J. Circadian variation of 5-fluorouracil plasma levels during continuous infusion 5-FU and leucovorin in patients with hepatic or renal dysfunction. Ann. Oncol., 5 (Suppl. 5): 236, 1994.